paclitaxel has been researched along with Intermittent Claudication in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (70.83) | 24.3611 |
| 2020's | 7 (29.17) | 2.80 |
| Authors | Studies |
|---|---|
| Alfonso, F; Donas, KP; Pitoulias, GA; Sohr, A; Torsello, G | 1 |
| Behrendt, CA; Bertges, DJ; Debus, ES; Kölbel, T; Kreutzburg, T; L'Hoest, H; Larena-Avellaneda, A; Peters, F; Schermerhorn, M; Sedrakyan, A | 1 |
| Batchelder, A; Davies, R; Diamantopoulos, A; Lea, T; Saha, P; Saratzis, A; Saratzis, N; Thomson, B; Yap, T; Zayed, H | 1 |
| Benko, A; Brodmann, M; Choi, D; Dobranszki, R; Guo, J; Jaff, MR; Micari, A; Stavroulakis, K; Tepe, G; Torsello, G; Vermassen, FEG; Veroux, P; Zeller, T | 1 |
| Ansel, G; Brodmann, M; Gao, Q; Krishnan, P; Laird, J; Mauri, L; Micari, A; Ouriel, K; Schneider, PA; Shishehbor, MH; Soga, Y; Zeller, T | 1 |
| Kavala, AA; Kuserli, Y; Turkyilmaz, S | 1 |
| Bajardi, G; Dinoto, E; Ferlito, F; Mirabella, D; Pakeliani, D; Pecoraro, F | 1 |
| Boesmans, E; Defraigne, JO; Deloge, C; Van Damme, H | 1 |
| Amann-Vesti, B; Blessing, E; Jaff, MR; Krzanowski, M; Langhoff, R; Peeters, P; Rocha-Singh, KJ; Scheinert, D; Sixt, S; Tepe, G; Torsello, G; Zeller, T | 1 |
| Brodmann, M; Frost, M; Keirse, K; Micari, A; Peeters, P; Tepe, G; Wang, H; Zeller, T | 1 |
| Ansel, GM; Brodmann, M; Jaff, MR; Keirse, K; Li, P; Micari, A; Peeters, P; Rocha-Singh, KJ; Scheinert, D; Schmahl, R; Tepe, G; Zeller, T | 1 |
| Chervenkoff, V; Esposito, G; Gerardi, D; Giugliano, G; Goverde, P; Kotasov, D; Magliulo, F; Stabile, E; Taeymans, K; Trimarco, B; Zhelev, D | 1 |
| Holewijn, S; Keirse, K; Lee, SW; Li, P; Micari, A; Reijnen, MMPJ; van Wijck, I; Veroux, P; Voulgaraki, D; Zeller, T | 1 |
| McDonald, RR; Thomas, SD; Varcoe, RL | 1 |
| Awata, M; Iida, O; Ishihara, T; Nanto, S; Shiraki, T; Uematsu, M | 1 |
| Herten, M; Imm, B; Osada, N; Schönefeld, E; Stahlhoff, S; Torsello, GB | 1 |
| Chaillou, P; Costargent, A; Davaine, JM; Gouëffic, Y; Guyomarch, B; Kaladji, A; Querat, J; Quillard, T | 1 |
| Tsai, TT | 1 |
| Beschorner, U; Bosiers, M; Brodmann, M; Deloose, K; Peeters, P; Pilger, E; Rastan, A; Scheinert, D; Schulte, KL; Zeller, T | 1 |
| Dansey, K; Shames, M; Wooster, M | 1 |
| Ansel, GM; Dake, MD; Jaff, MR; Machan, LS; O'Leary, EE; Ohki, T; Ragheb, AO; Saxon, RR; Smouse, HB; Snyder, SA; Zeller, T | 1 |
| Banning-Eichenseer, U; Bausback, Y; Bräunlich, S; Scheinert, D; Schmidt, A; Steiner, S; Ulrich, M | 1 |
| Ketelsen, D; Müller-Hülsbeck, S; Ricke, J; Rosenfield, K; Scheinert, D; Schmidt, A; Schröder, H; Sixt, S; Steiner, S; Weiss, N; Zeller, T | 1 |
| Kret, MR; Lee, JT; Tran, K; Ullery, BW | 1 |
4 trial(s) available for paclitaxel and Intermittent Claudication
| Article | Year |
|---|---|
Directional Atherectomy Followed by a Paclitaxel-Coated Balloon to Inhibit Restenosis and Maintain Vessel Patency: Twelve-Month Results of the DEFINITIVE AR Study.
Topics: Aged; Angioplasty, Balloon; Atherectomy; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Europe; Female; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Pilot Projects; Prospective Studies; Recurrence; Risk Factors; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Calcification; Vascular Patency | 2017 |
Paclitaxel-Coated Balloon in Infrapopliteal Arteries: 12-Month Results From the BIOLUX P-II Randomized Trial (BIOTRONIK'S-First in Man study of the Passeo-18 LUX drug releasing PTA Balloon Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjec
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Female; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Radiography; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency; Young Adult | 2015 |
Durable Clinical Effectiveness With Paclitaxel-Eluting Stents in the Femoropopliteal Artery: 5-Year Results of the Zilver PTX Randomized Trial.
Topics: Adult; Aged; Angioplasty; Anticoagulants; Arterial Occlusive Diseases; Aspirin; Clopidogrel; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Drug-Eluting Stents; Equipment Failure; Female; Femoral Artery; Follow-Up Studies; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Popliteal Artery; Recurrence; Stents; Ticlopidine; Vascular Patency | 2016 |
German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Germany; Humans; Intermittent Claudication; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Single-Blind Method; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
20 other study(ies) available for paclitaxel and Intermittent Claudication
| Article | Year |
|---|---|
Long-Term Mortality of Matched Patients with Intermittent Claudication Treated by High-Dose Paclitaxel-Coated Balloon Versus Plain Balloon Angioplasty: A Real-World Study.
Topics: Aged; Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Female; Humans; Intermittent Claudication; Male; Paclitaxel; Prospective Studies; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tubulin Modulators | 2020 |
Editor's Choice - Long Term Survival after Femoropopliteal Artery Revascularisation with Paclitaxel Coated Devices: A Propensity Score Matched Cohort Analysis.
Topics: Aged; Aged, 80 and over; Cardiovascular Agents; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Retrospective Studies; Vascular Access Devices | 2020 |
Paclitaxel and Mortality Following Peripheral Angioplasty: An Adjusted and Case Matched Multicentre Analysis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Databases, Factual; Drug-Eluting Stents; England; Female; Femoral Artery; Greece; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prosthesis Design; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Three-Year Sustained Clinical Efficacy of Drug-Coated Balloon Angioplasty in a Real-World Femoropopliteal Cohort.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recovery of Function; Registries; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2020 |
Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices | 2020 |
Comparison of paclitaxel-coated balloon angioplasty with femoropopliteal bypass surgery in treating femoropopliteal lesions.
Topics: Aged; Angioplasty, Balloon; Blood Vessel Prosthesis Implantation; Cardiovascular Agents; Coated Materials, Biocompatible; Disease-Free Survival; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Retrospective Studies; Time Factors; Vascular Access Devices; Vascular Patency | 2021 |
Efficacy and one-year outcomes of Luminor® paclitaxel-coated drug-eluting balloon in the treatment of popliteal artery atherosclerosis lesions.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Plaque, Atherosclerotic; Popliteal Artery; Prospective Studies; Recurrence; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2021 |
Revascularization of the superficial femoral artery with paclitaxel-coated balloon for claudication.
Topics: Aged; Angiography; Angioplasty, Balloon; Cohort Studies; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Humans; Intermittent Claudication; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prospective Studies; Risk Assessment; Treatment Outcome; Vascular Patency | 2018 |
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain: 2-Year Results From the IN.PACT Global Study.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2018 |
Drug-Coated Balloon Treatment of Femoropopliteal Lesions for Patients With Intermittent Claudication and Ischemic Rest Pain.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
One-Year Clinical Outcomes of the Legflow Drug-Coated Balloon for the Treatment of Femoropopliteal Occlusions Registry.
Topics: Aged; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Europe; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Registries; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2019 |
Outcomes After Drug-Coated Balloon Treatment of Femoropopliteal Lesions in Patients With Critical Limb Ischemia: A Post Hoc Analysis From the IN.PACT Global Study.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Clinical Trials as Topic; Coated Materials, Biocompatible; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Progression-Free Survival; Risk Factors; Time Factors; Vascular Access Devices; Vascular Patency | 2019 |
Vasculitis resulting from a superficial femoral artery angioplasty with a paclitaxel-eluting balloon.
Topics: Aged; Angioplasty, Balloon; Biopsy; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Femoral Artery; Humans; Intermittent Claudication; Paclitaxel; Treatment Outcome; Vascular Access Devices; Vascular Patency; Vasculitis | 2014 |
Angioscopically apparent large thrombus and uncovered stent struts 6 months after late stent thrombosis of a paclitaxel-coated nitinol drug-eluting stent implanted in the superficial femoral artery.
Topics: Aged; Alloys; Angiography; Angioscopy; Antineoplastic Agents, Phytogenic; Drug-Eluting Stents; Female; Femoral Artery; Follow-Up Studies; Graft Occlusion, Vascular; Humans; Intermittent Claudication; Paclitaxel; Prosthesis Failure; Thrombosis; Time Factors | 2014 |
Drug-eluting balloons for femoropopliteal lesions show better performance in de novo stenosis or occlusion than in restenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Critical Illness; Equipment Design; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Recurrence; Stents; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2015 |
Treatment of TASC C and D Femoropoliteal Lesions with Paclitaxel eluting Stents: 12 month Results of the STELLA-PTX Registry.
Topics: Aged; Combined Modality Therapy; Drug-Eluting Stents; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Prospective Studies; Registries; Time Factors | 2015 |
Missing the Forest for the Trees?: Drug-Eluting Balloon Treatment for Infrapopliteal Disease.
Topics: Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Female; Humans; Intermittent Claudication; Ischemia; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Vascular Access Devices | 2015 |
Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
Topics: Aged; Amputation, Surgical; Cardiovascular Agents; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Limb Salvage; Male; Middle Aged; Paclitaxel; Peripheral Arterial Disease; Prosthesis Design; Recurrence; Registries; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Vascular Patency | 2016 |
Single-Center Experience With Lutonix Drug-Coated Balloons in Infrapopliteal Arteries.
Topics: Aged; Aged, 80 and over; Amputation, Surgical; Angioplasty, Balloon; Cardiovascular Agents; Coated Materials, Biocompatible; Constriction, Pathologic; Female; Germany; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Paclitaxel; Peripheral Arterial Disease; Popliteal Artery; Recurrence; Retrospective Studies; Time Factors; Treatment Outcome; Vascular Access Devices; Vascular Patency | 2016 |
Real-World Performance of Paclitaxel Drug-Eluting Bare Metal Stenting (Zilver PTX) for the Treatment of Femoropopliteal Occlusive Disease.
Topics: Adult; Aged; Aged, 80 and over; Arterial Occlusive Diseases; Cardiovascular Agents; Constriction, Pathologic; Critical Illness; Disease-Free Survival; Drug-Eluting Stents; Endovascular Procedures; Female; Femoral Artery; Humans; Intermittent Claudication; Ischemia; Kaplan-Meier Estimate; Limb Salvage; Male; Metals; Middle Aged; Multivariate Analysis; Paclitaxel; Popliteal Artery; Proportional Hazards Models; Prosthesis Design; Prosthesis Failure; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index; Time Factors; Treatment Outcome; Vascular Patency | 2017 |